Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2010

View Archived Issues

Clinical data support potential of rufinamide for neuropathic pain

Cypher sirolimus-eluting stent superior to Endeavor zotarolimus-eluting stent in phase III trial

BT-061 improves psoriasis in double-blind trial

New fatty-acid amide hydrolase 1 inhibitor JNJ-40355003 has preclinical analgesic effects

Boehringer Ingelheim claims new bradykinin B1 receptor antagonists

FDA grants orphan drug status for BDM-E in retinitis pigmentosa

GSK presents new prostanoid DP1 receptor antagonists

NicOx and Merck & Co. expand license agreement for new NO donors

Mimetica describes new melanocortin MC1 receptor agonists

Galderma claims new inhibitors of ACAT-1

Micrus Endovascular stockholders approve merger with Johnson & Johnson

Respiratorius describes new bronchorelaxants

FDA approves Savient Pharmaceuticals' pegloticase for gout

Eisai claims new inhibitors of beta-amyloid peptide production

Synta Pharma expands phase II STA-9090 trial in NSCLC

BioCryst presents data from forodesine oncology studies

GTx-758 induces medical castration in phase II trial

Neurocrine reports data on GSK-561679 in major depressive disorder

Mochida Pharmaceutical files NDA in Japan for escitalopram

FDA grants fast track status for ARC-4558 in diabetes-associated pain

Pepscan Therapeutics and Tibotec form research collaboration

NexMed changes name to Apricus Biosciences

FDA extends review date for AstraZeneca's Brilinta NDA in ACS

FDA accepts Sanofi Pasteur's sBLA for Fluzone vaccine

BTG initiates first of three phase III studies of Varisolve in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...